Journal of Clinical Endocrinology & Metabolism · 2001 · Clinical trial
Explore the library
Limited human evidenceSynthetic hexapeptide secretagogue
Hexarelin
Hexarelin is a synthetic hexapeptide in the growth hormone secretagogue family. It has been investigated in endocrine physiology rather than established as a general recovery therapy.
Also indexed as: Examorelin
A clear starting point
Hexarelin is a synthetic hexapeptide in the growth hormone secretagogue family. It has been investigated in endocrine physiology rather than established as a general recovery therapy.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Ghrelin / GH–IGF-1
Hexarelin is a synthetic hexapeptide in the growth hormone secretagogue family. It has been investigated in endocrine physiology rather than established as a general recovery therapy.
- Targets & processes
- Ghrelin / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Pituitary endocrine responses compared with ghrelin and GHRH.
What this does not establish
A small human physiology study demonstrates hormone responses, not long-term clinical or athletic benefit.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
GH, cortisol and prolactin responses may differ by context. Glucose effects, fluid retention and long-term endocrine risks require clinical study.
Contraindications & cautions
Not an exhaustive contraindication review. GH, cortisol and prolactin responses may differ by context. Glucose effects, fluid retention and long-term endocrine risks require clinical study.
Medication & supplement interactions
Interaction information is incomplete. GH, cortisol and prolactin responses may differ by context. Glucose effects, fluid retention and long-term endocrine risks require clinical study.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
This is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.